Description
Radiglip-M 50 mg + 1000 mg is a combination oral medication used to manage type 2 diabetes mellitus in adults. It combines two antidiabetic agents: sitagliptin (50 mg), a DPP-4 inhibitor, and metformin hydrochloride (1000 mg), a biguanide. Sitagliptin enhances insulin secretion and reduces glucagon levels in the bloodstream, especially after meals, while metformin decreases hepatic glucose production and improves insulin sensitivity. This dual-action approach helps lower blood sugar levels effectively.
The extended-release formulation allows for once-daily dosing, typically with meals, to improve patient adherence and minimize gastrointestinal side effects associated with metformin. The recommended starting dose for patients not currently on metformin is 50 mg sitagliptin/500 mg metformin twice daily, gradually increased to 50 mg sitagliptin/1000 mg metformin twice daily. For patients already on metformin 850 mg twice daily, the recommended starting dose is 50 mg sitagliptin/1000 mg metformin twice daily. However, dosage adjustments should be individualized based on the patient's current regimen, effectiveness, and tolerability.
 ..jpeg)
 25MG.jpeg)
 ..jpeg)
 20MG.jpeg)
.jpeg)
 10MG.jpeg)
 1GM.jpeg)
60 MG.jpeg)
 2GM.jpeg)
Change Language